Senores Pharmaceuticals Limited has informed the Exchange regarding copy of Newspaper Publication for Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals has published its unaudited Q1 FY26 results in the Financial Express (English and Gujarati editions) on July 24, 2025, as required under SEBI listing rules. On a consolidated basis, total income rose to ₹141.35 crore from ₹80.87 crore in the same quarter last year, a jump of about 75% year-on-year. Consolidated net profit nearly doubled to ₹21.18 crore from ₹10.91 crore year-on-year, with diluted EPS at ₹4.60 versus ₹3.39. On a standalone basis, total income grew to ₹28.21 crore from ₹9.93 crore, and net profit climbed to ₹2.70 crore from ₹0.31 crore, reflecting strong business expansion.
The results show sharp year-on-year growth in both revenue and profit, which is a positive signal for shareholders and could support the stock price in the short term.